M&G Plc (MNG), the London-headquartered asset management and savings group, has disclosed a significant increase in its shareholding in Ondine Biomedical Inc, a non-UK issuer listed under ISIN CA68234M2058. The holding rose to 16.986784% of voting rights following a placement of shares, with the threshold crossed on 23 October 2026. The notification was submitted to the issuer on 26 October 2026, triggering a major holdings disclosure under standard TR-1 reporting requirements. Investors in both companies may be watching this development closely given the scale of the position now held.

Key Points

  • M&G Plc (MNG), registered in London, United Kingdom
  • M&G's voting rights in Ondine Biomedical Inc increased from 14.294787% to 16.986784% following a share placement
  • Total voting rights held now stand at 661,218,135, with 112,319,696 held as direct voting rights
  • Investors should watch whether M&G makes further disclosures regarding its strategic intent in Ondine Biomedical

M&G Plc Crosses New Threshold in Ondine Biomedical via Share Placement

The announcement confirms that M&G Plc's total position in Ondine Biomedical Inc reached 16.986784% of voting rights on 23 October 2026, up from a previously notified position of 14.294787%. The reason given for the notification is described simply as a placement of shares. The disclosure was completed on 26 October 2026 from London. All voting rights are attached directly to shares under DTR5.1, with no voting rights held through financial instruments reported in this notification. The movement represents a meaningful uplift in M&G's exposure to the Canadian-incorporated biomedical company.

Direct Voting Rights of 112,319,696 Shares Held Through M&G Investment Management

According to the TR-1 form, M&G holds 112,319,696 shares carrying direct voting rights in Ondine Biomedical, representing 16.986784% of the issuer's total voting rights. The full chain of ownership runs from M&G Plc as the ultimate controlling entity, through M&G Group Regulated Entity Holding Company Limited, M&G Group Limited, M&G FA Limited, and ultimately to M&G Investment Management Limited, which is a wholly owned subsidiary of M&G FA Limited. Each entity in the chain is recorded as holding the same aggregated percentage, consistent with the group's consolidated reporting structure.

Ondine Biomedical Inc: A Non-UK Issuer With a Canadian ISIN

Ondine Biomedical Inc is identified in the disclosure as a non-UK issuer, incorporated under Canadian ISIN CA68234M2058. The company operates in the biomedical sector, though the announcement does not provide further detail on its specific products, revenues, or financial performance. M&G's growing stake — now surpassing the 15% mark — places it as a substantial shareholder in the business. The scale of the position, and the mechanism of a share placement triggering the threshold crossing, may prompt investors to assess the strategic rationale behind M&G's continued accumulation of shares in this issuer.